Thrombosis and Coagulopathy in COVID-19

Juan Esteban Gómez-Mesa, MD, FSIAC,
Stephania Galindo-Coral, MD,
Maria Claudia Montes, MD, and
Andrés J. Muñoz Martin, MD, PhD

Abstract: Since December 2019, an outbreak of coronavirus disease 2019 (*COVID-19*) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (*COVID-19*) as a pandemic. The presence of comorbidities (*eg, cardiovascular disease, obesity*), Sepsis Induced Coagulopathy score >4, elevation of D-dimer (*>6 times the normal value*), C-reactive protein, troponins and other disseminated intravascular coagulation markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 (*PaO2/FiO2*) by mitigating the formation of microthrombi and associated pulmonary coagulopathy. (Curr Probl Cardiol 2021;46:100742.)

Epidemiology

Since December 2019, an outbreak of coronavirus disease 2019 (*COVID-19*) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world. On

February 11, 2020, the Coronavirus Study Group of the International Committee on Taxonomy of Viruses officially named the new coronavirus that causes COVID-19 as "severe acute respiratory syndrome coronavirus 2 (*SARS-CoV-2*)," and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (*COVID-19*) as a pandemic.[1-8]

This pandemic had its epicenter in the Asian continent (*China*), which later moved to the European continent (*mainly Italy and Spain*), and currently to the American continent, initially in the United States and now in United States and Latin America (*mainly Mexico and Brazil*) (Graphs 1-3).

Coronavirus-19 Infection

The "severe acute respiratory syndrome coronavirus 2 (*SARS-CoV-2*)" is a single stranded RNA coronavirus that enters the human cell mainly through binding to angiotensin converting enzyme 2 (*ACE 2*), expressed in increased amounts in the alveolar cell of the lung, cardiac myocytes, vascular endothelium, and other cells. SARS-CoV-2 is transmitted mainly after the viral particles are inhaled and enters the respiratory tract. This virus can survive for up to 24-72 hours on surfaces that allow its transmission.[1,6]

This respiratory viral infection produces the COVID-19, which is generally asymptomatic or with mild symptoms including fever, cough, fatigue, dyspnea, diarrhea, headache, and myalgia (*up to 81.4% of patients*). Severe cases are characterized by respiratory rate >30 bpm, arterial oxygen saturation <93% at rest, PaO2/FiO2 <300 mm Hg and/or infiltrates in >50% of lung fields in 24-48 hours (*up to 13.9% of patients*) and can progress to critically ill patients (*up to 4.7% of patients*), presenting rapid deterioration and development of acute respiratory distress syndrome, septic shock, metabolic acidosis and coagulopathy, including disseminated intravascular coagulation (*DIC*) and cytokine storm.[2,4,7-13]

These clinical manifestations, as well as the imaging and paraclinical alterations, vary as the pandemic evolves worldwide, and they also depend on the severity of the infection. A registry of 1099 laboratory-confirmed COVID-19 patients in 552 institutions in 30 provinces of China described some of these most frequent and relevant findings, observed in the first two months of this pandemic (Table 1).[8]

The most consistent hemostatic alterations with COVID-19 are thrombocytopenia and elevation of D-dimer, which are associated with a higher

Graph 1. Daily cases until September/2020. Comparison by regions. Image adapted from: https://covid19.who.int/.

4

Graph 2. Cumulative cases until September/2020. Comparison by regions. Image adapted from: https://covid19.who.int/.

Graph 3. Worldwide change of the Epicenter of the pandemic: Starting in Asia, then Europe and, currently, America (*North America and Latin America*). Image adapted from: https://vac-lshtm.shinyapps.io/ncov_tracker/.

requirement for mechanical ventilation, admission to intensive care, and death. It has been described that older patients and those with comorbidities have a higher risk of in-hospital mortality, and in these 2 groups of patients there are also higher levels of D-dimer. Taking into account the clinical implications of the elevated D-dimer value or the marked elevations during follow-up (*3-4 times*), hospital management can be considered in this setting in the absence of other severe symptoms since this

TABLE 1. Most frequent clinical, imaging and paraclinical findings

	All (1.099)	Nonsevere (926)	Severe (173)
Most frequent symptoms			
Cough	745 (67.8%)	623 (67.3%)	122 (70.5%)
Fever on admission (>37.5˚C)	473/1081 (43.8%)	391/910 (43%)	82/171 (48%)
Fatigue or tiredness	419 (38.1%)	350 (37.8%)	69 (39.9%)
Sputum production	370 (33.7%)	309 (33.4%)	61 (35.3%)
Shortness of breath	205 (18.7%)	140 (15.1%)	65 (37.6%)
Myalgia or arthralgia	164 (14.9%)	134 (14.5%)	30 (17.3%)
Odynophagia	153 (13.9%)	130 (14.0%)	23 (13.3%)
Headache	150 (13.6%)	124 (13.4%)	26 (15.0%)
Chill	126 (11.5%)	100 (10.8%)	26 (15.0%)
Imaging findings			
Chest X-ray changes	162/274 (59.1%)	116/214 (54.2%)	46/60 (76.7%)
Chest CT alterations	840/975 (86.2%)	682/808 (84.4%)	158/167 (94.6%)
Laboratory findings			
White blood cell count <4,000 mm³	330/978 (33.7%)	228/811 (28.1%)	102/167 (61.1%)
Lymphocyte count <1,500 mm³	731/879 (83.2%)	584/726 (80.4%)	147/153 (96.1%)
Platelet count <150,000 mm³	315/869 (36.2%)	225/713 (31.6%)	90/156 (57.7%)
C-reactive protein ≥10 mg / L	481/793 (60.7%)	371/658 (56.4%)	110/135 (81.5%)
D-dimer ≥0.5 mg/L	260/560 (46.4%)	195/451 (43.2%)	65/109 (59.6%)

indicates an increase in thrombin generation and a greater risk of complications (Tables 2 and 3).[14-16]

Coagulopathy

In hospitalized patients for suspected or confirmed COVID-19, a coagulation profile should be performed, including D-dimer, partial thromboplastin, *partial thromboplastin*time, platelet count, and fibrinogen. Alterations in these parameters can occur 7-11 days after the onset of symptoms or 4-10 days after hospitalization. Repeating these coagulopathy parameters (*D-dimer, prothrombin time, and platelet count*) are recommended in patients with severe COVID-19, at least every 2-3 days.[6,15]

The combination of thrombocytopenia, prolonged PT, and elevated D-dimer suggests DIC, however, its presentation is different from the presentation seen in sepsis, where thrombocytopenia is much more profound and the elevation of D-dimer does not reach the values observed in COVID-19 cases. Current evidence suggests COVID-19 associated coagulopathy is a combination of low-grade DIC and pulmonary thrombotic microangiopathy, which could have a significant impact on organ dysfunction in most patients with severe disease.[14]

The presence of coagulopathy as part of the systemic inflammatory response syndrome is a common feature of severe COVID-19.

TABLE 2. Conditions associated with hospital mortality

	Total (n = 191)	Death (n = 54)	Alive (n = 137)	P value	OR (95% CI)	
					Univariable	Multivariable
Demographic conditions						
Age, years. Median (IQR)	56 (46 - 67)	69 (63 − 76)	52 (45 − 58)	<0.0001	1.14 (1.09-1.18) P < 0.0001	1.10 (1.03-1.17) P = 0.0043
Arterial hypertension. n (%)	58 (30%)	26 (48%)	32 (23%)	0.0008	3.05 (1.57-5.92) P = 0.001	
Diabetes mellitus. n (%)	36 (19%)	17 (31%)	19 (14%)	0.0051	2.85 (1.35-6.05) P = 0.0062	
Coronary heart disease. n (%)	15 (8%)	13 (24%)	2 (1%)	<0.0001	21.40 (4.64-98.76) P < 0.0001	2.14 (0.26-17.79) P =0.48
COPD. n (%)	6 (3%)	4 (7%)	2 (1%)	0.047		
Respiratory rate> 24 bpm. n (%)	56 (29%)	34 (63%)	22 (16%)	<0.0001	8.89 (4.34-18.19) P < 0·0001	
SOFA score. Median (IQR)	2 (1 - 4)	4.5 (4 − 6)	1 (1 − 2)	<0.0001	6.14 (3.48-10.85) P < 0·0001	
Laboratory findings						
Leukocytes, >10,000 mm^3. n (%)	40 (21%)	25 (46%)	15 (11%)	<0·0001	6.60 (3.02-14.41) P < 0·0001	
Lymphocytes, <800 mm^3. n (%)	77 (40%)	41 (76%)	36 (26%)	<0.0001	0.02 (0.01-0.08) P < 0·0001	0.19 (0.02-1.62) p = 0·13
Anemia. n (%)	29 (15%)	14 (26%)	15 (11%)	0.0094		
Platelets, <100,000 mm3. n (%)	13 (7%)	11 (20%)	2 (1%)	<0.0001		
Albumin, mg/dL. n (%)	3.2 (2.9-3.5)	2.91 (2.65-3.13)	3.36 (3.06-3.64)	<0.0001		
ALT >40, U/L. n/N (%)	59/189 (31%)	26 (48%)	33/135 (24%)	0.0015	2.87 (1.48-5.57) P = 0·0018	
LDH >245, U/L. n/N (%)	123/184 (67%)	53 (98%)	70/130 (54%)	<0.0001		

TABLE 2. (*continued*)

	Total (n = 191)	Death (n = 54)	Alive (n = 137)	P value	OR (95% CI) Univariable	Multivariable
Troponin I HS >28, pg/mL. n/N (%)	24/145 (17%)	23/50 (46%)	1/95 (1%)	<0.0001	45.43 (6.10-338.44) P = 0·0002 80.07 (10.34-620.36) P =< 0·0001	
D-dimer >1, μg/mL. n/N (%)	72/172 (42%)	44 (81%)	28/118 (24%)	<0·0001	20.04 (6.52-61.56) P =< 0·0001	18.42 (2.64-128.55) P = 0.0033
Prothrombin time, ≥16. n/N (%)	11/182 (6%)	7 (13%)	4/128 (3%)	0·0004	4.62 (1·29-16.50) P = 0.019	
Ferritin, ug/L (>300). n/N (%)	102/128 (80%)	44/46 (96%)	58/82 (71%)	0·0008	9.10 (2.04-40.58) P = 0.0038	
Interventions						
Steroid use. n (%)	57 (30%)	26 (48%)	31 (23%)	0.0005		
Immunoglobulin IV. n (%)	46 (24%)	36 (67%)	10 (7%)	<0.0001		
Oxygen by high flow nasal cannula. n (%)	41 (21%)	33 (61%)	8 (6%)	<0.0001		
Noninvasive MV. n (%)	26 (14%)	24 (44%)	2 (1%)	<0.0001		
Invasive VM. n (%)	31 (17%)	31 (57%)	1 (1%)	<0.0001		
ECMO. n (%)	3 (2%)	3 (6%)	0	0.0054		
Renal replacement therapy. n (%)	10 (5%)	10 (19%)	0	<0.0001		

IV, intravenous; MV, mechanical ventilation; ECMO, extracorporeal membrane oxygenation system; SOFA, sequential organ failure assessment.

TABLE 3. Poor prognosis indicators

Parameter	Value
Age	52 years (alive) vs 69 years (dead)
SOFA score	>2.0
D-dimer	>0.5 mg/L
Thrombocytopenia	<100,000
Prothrombin time	Increase >3 seconds
Activated partial thromboplastin time	Increase >5 seconds
Fibrinogen	<1.5 gm/l
Sepsis-Induced Coagulopathy (SIC) score	≥4
Respiratory frequency	>24 bpm
Heart rate	>125 bpm

Approximately 20%-50% of hospitalized patients with COVID-19 have hematologic changes in coagulation tests (*elevated D-dimer, prolonged PT, thrombocytopenia, and/or low fibrinogen levels*). This condition is characterized by more thrombotic than hemorrhagic events that are associated with coagulopathy (*specifically* venous thromboembolism [*VTE*]). On the other hand, endothelial dysfunction results in high levels of D-dimer, thrombin and fibrin degradation products, thrombocytopenia and prolonged clotting times, which leads to hypoxia and pulmonary congestion mediated by thrombosis and microvascular occlusion, in addition to thrombosis of central lines and catheters and vascular occlusive events (*cerebrovascular events, limb ischemia, etc*) that generally occur in the intensive care units.[6,10,15,17-19]

Fibrin and thrombin deposition occurs mainly in the pulmonary microvasculature, being a factor that contributes to acute respiratory distress syndrome and coagulopathy in patients who die from COVID-19. Furthermore, the hypoxia that occurs in severe COVID-19 can aggravate thrombosis not only by increasing the viscosity of the blood, but also through the hypoxia-inducible transcription factor-dependent signaling pathway.[10,17,20]

Similar to the endothelial dysfunction of sepsis induced coagulopathy (SIC), in which there is excessive thrombin generation and impaired fibrinolysis, there is a type of endotheliopathy that appears to contribute to the pathophysiology of microcirculatory changes in SARS-CoV-2 infection. The receptor for viral adhesion is an angiotensin-converting enzyme-2 receptor on endothelial cells, and viral replication causes inflammatory cell infiltration, endothelial apoptosis, and microvascular prothrombotic events. Viral inclusions within endothelial cells and mononuclear and polymorphonuclear cell infiltration have been observed, with evidence of endothelial apoptosis in postmortem analysis of SARS-Cov-2 infection.

As a result of this, microcirculatory dysfunction contributes to the clinical sequelae of COVID-19 patients.[6,10] Other abnormalities that may be relevant in the context of coagulopathy are decreased fibrinogen, elevated Lactate dehydrogenase (LDH), and, in some patients, markedly elevated serum ferritin values.[20]

Another important characteristic of COVID-19 infection is the procoagulant response in its acute phase, where acute phase reactants (*such as Factor VIII, Von Willebrand Factor, and fibrinogen*) are associated with an increased risk of thrombosis directly related to elevated levels of fibrinogen. In severe stages of the disease, there is an increase in inflammatory cytokines (*tumor necrosis factor and interleukins, including interleukin 1 and interleukin 6*). IL-6 induces expression of tissue factor in macrophages, which initiates the activation of coagulation and generation of thrombin. Tumor necrosis factor and IL-1 are the main mediators of the suppression of the endogenous coagulation cascade. In a group of severely compromised COVID-10 patients, a cytokine storm characterized by high concentrations of proinflammatory cytokines and chemokines may be found.[12,14]

The International Society of Thrombosis and Haemostasis proposed a new category to identify an early stage of DIC associated with sepsis, which is called SIC. This score can be applied to COVID-19 patients, and those who meet these criteria benefit from anticoagulant management (Table 4).[7,10]

Up to 71.4% of patients who die from COVID-19 have DIC, while it occurs in only 0.6% in those who survive. The main alteration of this coagulopathy is the marked elevation of D-dimer without a drop in platelets or a prolongation of clotting times, which suggests a process of generation of thrombin and local rather than systemic fibrinolysis. D-dimer value >2.0 ug/mL at admission or its increase during hospitalization (*up to 3-4 times*) have been associated with higher hospital mortality.[18,20-22]

The worsening of laboratory parameters related to coagulation indicates progression in the severity of COVID-19 infection and predicts the

TABLE 4. ISTH score - Sepsis Induced Coagulopathy (*SIC*)

ITEM	SCORE	VALUE
Platelet count (× mm³)	1	100.000-150.000
	2	<100.000
PT - INR	1	1.2-1.4
	2	>1.4
SOFA score	1	1
	2	≥2
	≥ 4	

need for greater and more aggressive intensive care, while the improvement of these parameters, together with the improvement or clinical stability suggests an adequate evolution.[18]

VTE

COVID-19 infection can predispose to VTE or arterial due to the presence of increased inflammatory response, hypoxia, immobilization, and DIC.[7,10,21]

The risk of developing VTE in critically ill patients is higher in the presence of COVID-19. In addition to hemostatic alterations; immobility, systemic inflammatory status, mechanical ventilation, and central catheters increase the risk of thromboembolic events, while nutritional and hepatic alterations vary the production of coagulation factors.[1] There are several studies that support the increased incidence of VTE in COVID-19 patients and their risk factors,[13,21,23-25] (Table 5). Other study found that the proportion of patients with VTE was higher in the intensive care unit (ICU) patients (*47%; 95% confidence interval, 36-58*) than in the general ward patients (*3.3%; 95% confidence interval, 1.3-8.1*) (Table 6); the risk factors for VTE that were identified include ICU hospitalization, higher leukocyte count, higher neutrophil/lymphocyte ratio, and higher D-dimer value.[25]

In patients with sudden deterioration in oxygen saturation, respiratory distress, low blood pressure, or right ventricular (RV) dysfunction, the possibility of pulmonary embolism (PE) should be considered. Diagnosis can be difficult as COVID-19 patients may have an elevated D-dimer value even in the absence of VTE. Imaging studies cannot be done routinely due to the risk of transmission of the infection, the limitations to transfer and the clinical instability that the patient could present at any given time. In these cases, and taking into account the value of D-dimer, the use of anticoagulants at therapeutic, intermediate doses or as prophylaxis could be considered. The use of tests at the patient side, such as compression ultrasonography for the diagnosis of deep vein thrombosis and echocardiography to evaluate RV strain associated with PE, can be difficult in unstable, prone, or critically ill patients; also, without having sufficient specificity and sensitivity to diagnose VTE, in certain clinical scenarios they can increase the index of clinical suspicion, and its use may be considered.[1,25]

Thromboprophylaxis

Hospitalized patients with COVID-19 present similar intrinsic and extrinsic risk factors for VTE to the rest of the hospitalized population, such as advanced age, obesity, immobilization, neurological events,

TABLE 5. Venous thromboembolism incidence studies for COVID-19 patients

Author, year	n	Outcome	Tests	Treatment	Findings

Cui S et al, 2020[23]	81	Incidence of VTE in ICU	-rTR-PCR for SARS-COV-2
			  -CT
			  -LL venous Doppler ultrasound
			  -Clinical examination
			  -Laboratory tests
				-Antiviral
				  -Supportive
				  -None
				  -Thromboprophylaxis
					-20/81 (25%) VTE
					  -8/81 (10%) died
					  -D-dimer cut-off point of 1.5 ug/L for VTE with a S: 85%, E:88.6%, PPV: 70.8% and NPV: 94.7%

Zhang L et al, 2020[24]	143	Incidence of DVT in hospitalized	-LL venous Doppler ultrasound
			  -Ecocardiography
			  -Laboratory test
			  -CT
			  -Prediction scores for risk of VTE
				-Antiviral
				  -Antibiotic
				  -Glucocorticoid
				  -Antihypertensive
				  -Immunoglobulin
				  -Thromboprophylaxis
					-66/143 (46%) DVT.
					  -23/66 (34.8%)proximal DVT
					  -43/66 (65.2%) distal DVT
					  -CURB-65 score 3 to 5, Padua score $\geq$4 and D-dimer >1.0 ug/mL for DVT screening with S: 88.52% and E: 61.43%.

Middeldrop S et al, 2020[25]	198	Incidence of VTE in hospitalized patients	-rTR-PCR for SARS-COV-2
			  -CT
			  -LL venous Doppler ultrasound
			  -Laboratory test
				-Thromboprophylaxis
				  -Anticoagulation
					-39/198 (20%) VTE
					  -14/198 (7.1%) proximal DVT
					  -11/198 (5.6%) distal DVT
					  -13/198 (6.6%) PTE with/without DVT

Klok FA et al, 2020[21]	184	Incidence of the composite outcome of symptomatic acute PTE, DVT, ischemic stroke, myocardial infarction or systemic arterial embolism in ICU	-Laboratory test
			  -LL venous Doppler ultrasound
			  -CT angiogram
				Thromboprophylaxis (nadroparin)	-31% cumulative incidence of composite outcome
					  -27% cumulative incidence for VTE
					  -3.7% cumulative incidence for arterial thrombotic events

Lodigiani C et al, 2020[13]	388	Rate of venous and arterial thrombo embolic complication in hospitalized patients	-Laboratory test
			  -LL venous Doppler ultrasound
			  -CT angiogram
			  -ISTH score
				Thromboprophylaxis	-28/362 (7.7%) at least one thromboembolic complication
					  -16/362 (4.4%) VTE
					  -9/362 (2.5%) ischemic stroke
					  -4/362 (1.1%) acute coronary syndrome

TABLE 6. Cumulative incidence of VTE[24]

	Total VTE Asymptomatic	Symptomatic	VTE in ICU Asymptomatic	Symptomatic	VTE in general ward Asymptomatic and symptomatic
7 days	*16% (95% CI, 10-22)*	*10% (95% CI, 5.8-16)*	*26% (95% CI, 17-37)*	*15% (95% CI, 8.0-24)*	*(95% CI, 1.4-15)*
14 days	*33% (95% CI, 23-43)*	*21% (95% CI, 14-30)*	*47% (95% CI, 34-58)*	*28% (95% CI, 18-39)*	*9.2% (95% CI, 2.6-21)*
21 days	*42% (95% CI, 30-54)*	*25% (95% CI, 16-36)*	*59% (95% CI, 42-72)*	*34% (95% CI, 21-46)*	*9.2% (2.6-21)*

cancer, ICU management, previous thromboembolic events, or thrombophilia, however, prophylactic management in this population is currently a challenge (Table 7).[25]

Pharmacological thromboprophylaxis should then be considered in all hospitalized COVID-19 patients who are immobilized or severely ill, unless there are contraindications (*such as active bleeding or severe thrombocytopenia*). Different scales can be used to assess this hospital risk (*Padua, Caprini, IMPROVE*). The dose should be adjusted according to renal function. Although drug selection should be guided by available institutional protocols, the World Health Organization recommends the use of unfractionated or low molecular weight heparins (LMWHs) and, if contraindicated, mechanical thromboprophylaxis should be considered. Pharmacological thromboprophylaxis is recommended once a day, since it reduces the risk of missing additional doses and is also associated with less exposure of health personnel for its administration. If LMWH is not available, unfractionated heparin can be considered, keeping in mind that this requires more frequent injections and, therefore, greater exposure of health personnel. Fondaparinux can also be considered, but there is no

TABLE 7. Recommendations for thromboprophylaxis and/or anticoagulation

COVID-19 positive	Coagulation tests	Conventional thromboprophylaxis	Thromboprophylaxis in scalating doses	Anticoagulation
Ambulatory		Consider		
Hospitalized	X			
General ward	X	X		
ICU	X		X	
VTE confirmed	X			X
Confirmed PE	X			X
ARDS	X		X	

evidence that this molecule has the same anti-inflammatory properties as heparins. Patients with more severe infections may require higher doses of thromboprophylaxis due to their hypercoagulable state. The use of direct anticoagulants in thromboprophylaxis is not recommended in this context due to the possible drug interactions that may occur with the different drugs and therapies available and under investigation for the treatment of COVID-19.[4,14,15,25]

Some of the nonanticoagulant properties of LMWH include the potential for binding to inflammatory cytokines, inhibition of neutrophil chemotaxis and leukocyte migration, neutralization of positively charged complement factor C5a, and sequestration of acute phase proteins.[12,26]

Regarding the above, it is suggested that LMWH administered in the early stages of SARS-CoV2 infection can exert a positive effect not only in terms of preventing thrombosis but also reducing systemic and pulmonary inflammation and limiting viral invasion.[7,13] Other nonanticoagulant actions of heparin include its antiviral role (*experimental models*), decreased collagen deposits and antiarrhythmic properties (*animal models*), as well as modulation of endothelial dysfunction, improvement of microvascular dysfunction, and mitigation of pulmonary coagulopathy.[26,27]

In patients who remain completely immobilized, there may be an additional benefit with intermittent pneumatic compression in addition to drug thromboprophylaxis. This therapy should also be considered if there is severe thrombocytopenia (*platelets <25,000 to 50,000 × 10⁹/L*)[2,25,28,29]

The use of extended ambulatory thromboprophylaxis (*from 14 to 45 days*) should be considered in patients at high risk of VTE, independent of COVID-19 infection, and that includes reduced mobility, previous thromboembolic events, comorbidities (*eg, active cancer*) and Elevated D-dimer (*>2 times normal value*). Thromboprophylaxis for patients who are quarantined for mild COVID-19, but with significant comorbidities, or patients without COVID-19 but who are functionally severely limited by quarantine is not recommended. These patients should be advised to remain active at home.[1,2,25]

Anticoagulation

The presence of comorbidities (*eg, cardiovascular disease, obesity*), SIC score> 4, elevation of D-dimer (*>6 times the normal value*), C-reactive protein, troponins and other DIC markers; is associated to a worse

prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42% (Table 7).[25]

In this population, initial anticoagulant treatment with LMWH has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 ($PaO2/FiO2$) by mitigating the formation of microthrombi and associated pulmonary coagulopathy, also decreasing complementary inflammation.[26,30,31]

Anticoagulation should be considered if there is evidence of VTE or if the patient is anticoagulated, unless they have thrombocytopenia (*<50,000 × mm × or active bleeding*). The selected drug depends on kidney and liver function, platelet count, and gastrointestinal function.

TABLE 8. Drug interactions[5,7]

	Chloroquine / Hydroxychloroquine	Azithromycin	Lopinavir / Ritonavir	Cobicistat	Favipavir	Remdesivir	Oseltamivir	Ribavirin	Methyl prednisolone	Interferon	Tocilizumab
Heparin	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions
Enoxaparin	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions
Apixaban	Low risk	No interactions	Do not use	Do not use	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	High risk
Rivaroxaban	Low risk	High risk	Do not use	Do not use	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	High risk
Edoxaban	High risk	Do not use	High risk	Do not use	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions
Dabigatran	High risk	High risk	High risk	Do not use	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions	No interactions
Warfarin	No interactions	High risk	High risk	High risk	Do not use	No interactions	No interactions	High risk	High risk	High risk	No interactions

Legend: No interactions (green) · Low risk (yellow) · High risk (orange) · Do not use (red)

Parenteral anticoagulation is recommended in critically ill patients, as it can be temporarily suspended and has no interactions with drugs considered for the treatment of COVID-19. Given the exposure of health personnel with the use of unfractionated heparin by taking paraclinics and dose adjustment, the use of LMWH is preferred in these patients. The benefits of direct oral anticoagulants include no need for routine monitoring and easy outpatient management, however, potential risks may include their use in the presence of clinical deterioration and the lack of availability of a reversal agent in all institutions. In patients who are going to be discharged, the use of direct oral anticoagulants and LMWH should be preferred, avoiding frequent tests for INRs. The potential for drug interactions with potential treatments for COVID-19 should always be evaluated[1,5,7,14,18] (Table 8).

A 30%-50% decrease in platelet count from the start of heparin treatment (4-14 days) should suggest heparin-induced thrombocytopenia. The foregoing makes it necessary to suspend this anticoagulant treatment, and may explain some cases of limb ischemia that have been observed in cases of COVID-19.[15]

Conclusions

There are different ways in which the COVID-19 pandemic can affect the prevention and treatment of thrombotic or thromboembolic diseases. First, the direct effect of COVID-19 or the indirect effect related to the cytokine storm that precipitates the onset of the systemic inflammatory response syndrome and predisposes to the development of thrombotic events; second, the interventions available to treat COVID-19 (*eg, lopinavir/ritonavir, remdesivir, bevacizumab, tocilizumab, sarilumab, fingolimod, chloroquine/hydroxychloroquine, interferon, azithromycin*) may have drug interactions with antiplatelets and/or anticoagulants; and third, the pandemic, due to the redistribution of resources and social distancing recommendations, can adversely affect the care of patients without COVID-19 but who present thrombotic events and the fear of acquiring COVID-19 or presenting complications leads to not receiving or suspending the anticoagulant treatment.[1]

The protocols for thromboprophylaxis, anticoagulation, and additional considerations for the management of coagulopathy and bleeding should be implemented in each institution following the most current national and international recommendations.

REFERENCES

1. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thrombo-embolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. *J Am Coll Cardiol* 2020;75:2950–73. https://doi.org/10.1016/j.jacc.2020.04.031.

2. Boccia M, Aronne L, Celia B, et al. COVID-19 and coagulative axis: review of emerging aspects in a novel disease. *Monaldi Arch Chest Dis* 2020;90:271–6. https://doi.org/10.4081/monaldi.2020.1300.

3. Song JC, Wang G, Zhang W, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. *Mil Med Res* 2020;7:19. https://doi.org/10.1186/s40779-020-00247-7.

4. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance V 1.2. 2020;1−21

5. Günertem E, Akay T, Aliyev A, et al. Treatment and prophylaxis strategies for deep vein thrombosis during COVID-19 outbreak. *Turk J Vasc Surg* 2020;29:203–7. https://doi.org/10.9739/tjvs.2020.734.

6. Connors J, Levy J. COVID-19 and its implications for thrombosis and anticoagulation. *Blood. Blood.* 2020;135:2033–40. https://doi.org/10.1182/blood.2020006000.

7. Vivas D, Roldán V, Esteve-Pastor MA, et al. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología. *Rev Esp Cardiol* 2020;73:749–57. https://doi.org/10.1016/j.recesp.2020.04.006.

8. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708–20. https://doi.org/10.1056/NEJMoa2002032.

9. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. *JAMA* 2020;323:1612–4. https://doi.org/10.1001/jama.2020.4326.

10. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 in patients with coagulopathy. *J Thromb Haemost* 2020. https://doi.org/10.1111/jth.14817.

11. China CDC. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. *China CDC Weekly* 2020;2:113–22.

12. Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). *Blood Transfus* 2020;18:167–9. https://doi.org/10.2450/2020.0083-20.

13. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb Res* 2020;191:9–14. https://doi.org/10.1016/j.thromres.2020.04.024.

14. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol* 2020;7:e438–40. https://doi.org/10.1016/S2352-3026(20)30145-9.

15. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *J Thromb Haemost* 2020;18:1023–6. https://doi.org/10.1111/jth.14810.

16. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.

17. Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. *J Thromb Haemost* 2020;18:1752–5. https://doi.org/10.1111/jth.14828.

18. Hematology [internet]. Washington, DC. US; 2020. COVID-19 resources: COVID-19 and Coagulopathy: Frequently Asked Questions. 2020 Apr. [Cited: 2020 sept 27]. Available from : https://www.hematology.org/covid-19/covid-19-and-coagulopathy.

19. Lee SG, Fralick M, Sholzberg M. Coagulopathy associated with COVID-19. *CMAJ* 2020;192:E583. https://doi.org/10.1503/cmaj.200685.

20. Covid Treatment Group. Thromboprophylaxis and anticoagulation in COVID-19 infection. Imperial College Healthcare − NHS. V 0.1 08.04.2020

21. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res* 2020;191:145–7. https://doi.org/10.1016/j.thromres.2020.04.013.

22. Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. *J Thromb Haemost* 2020;18:1324–9. https://doi.org/10.1111/jth.14859.

23. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost* 2020;18:1421–4. https://doi.org/10.1111/jth.14830.

24. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost* 2020;18:1995–2002. https://doi.org/10.1111/jth.14888.

25. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost* 2020;18:1859–65. https://doi.org/10.1111/jth.14929.

26. Thachil J. The versatile heparin in COVID-19. *J Thromb Haemost* 2020;18:1020–2. https://doi.org/10.1111/jth.14821.

27. Menezes-Rodrigues FS, Padrão Tavares JG, Pires de Oliveira M, et al. Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients. *J Thromb Haemost* 2020;18:2073–5. https://doi.org/10.1111/jth.14902.

28. NICE guidelines venous thromboembolism: reducing the risk for patients in hospital. Available at: http://www.nice.org.uk/guidance/cg92

29. Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. *Blood Adv* 2018;2:3198–225. https://doi.org/10.1182/bloodadvances.2018022954.

30. Li J, Li Y, Yang B, et al. Low-molecular-weight heparin treatment for acute lung injury / acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. *Int J Clin Exp Med* 2018;11:414–22.

31. Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-inflammatory effects of heparin and its derivatives: a systematic review. *Adv Pharmacol Sci* 2015;2015:507151. https://doi.org/10.1155/2015/507151.